Top Medical News
Roshini Claire Anthony, 22 hours ago

Post-menopausal women diagnosed with oestrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery followed by whole breast radiotherapy have a reduced risk of developing local recurrence, according to a study from Italy.

Yesterday
A subclinical inflammatory state resulting from increased adiposity and metabolic dysfunction appears to contribute to breast cancer pathogenesis in Asian women, a Taiwan study has found.
Christina Lau, Yesterday

The first-line use of osimertinib in patients with EGFR mutation–positive advanced non-small-cell lung cancer (NSCLC) is associated with significant improvements in a number of post-progression endpoints compared with current standard of care (SoC), according to new data from the phase III FLAURA study.

Yesterday
Acute disruptions of a patient’s social support network, such as during divorce, seem to be linked to worse cancer outcomes, a recent study has shown.
Stephen Padilla, 2 days ago
Patient who have pterygium are at an increased risk of developing cutaneous melanoma (CM), according to a Western Australia (WA) study.
2 days ago
Sleep patterns appear to be disrupted in paediatric patients with medulloblastoma undergoing chemotherapy and may, in turn, negatively affect their mood, a recent study has shown.
2 days ago
Factors such as Barret’s oesophagus (BE) length, presence of low-grade dysplasia (LGD) and nodularity increase the risk of progression from nondysplastic (ND)BE or LGD to high-grade dysplasia or oesophageal adenocarcinoma, a study has found.
Special Reports
Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

29 Jan 2018

Role of comprehensive genomic profiling in personalized treatment

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Dr Joslyn Ngu, 04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Conference Reports
Roshini Claire Anthony, 24 Apr 2018

Post-menopausal women diagnosed with oestrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery followed by whole breast radiotherapy have a reduced risk of developing local recurrence, according to a study from Italy.

Christina Lau, 24 Apr 2018

The first-line use of osimertinib in patients with EGFR mutation–positive advanced non-small-cell lung cancer (NSCLC) is associated with significant improvements in a number of post-progression endpoints compared with current standard of care (SoC), according to new data from the phase III FLAURA study.

Christina Lau, 16 Apr 2018

MRI, with or without targeted biopsy, detects more clinically significant prostate cancer and less clinically insignificant prostate cancer than the standard transrectal ultrasonography (TRUS)-guided approach, enabling more than one-quarter of patients to safely avoid a biopsy altogether.

Christina Lau, 12 Apr 2018

Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.

Christina Lau, 02 Apr 2018

Patients with urologic cancers are more likely to attempt suicide, highlighting the need for increased psychiatric intervention for these patients at an earlier stage, according to findings presented at the European Association of Urology (EAU) 2018 Congress.

Roshini Claire Anthony, 07 Mar 2018

A combination of atezolizumab and bevacizumab demonstrated favourable progression-free survival (PFS) in patients with treatment-naïve advanced or metastatic renal cell carcinoma (RCC), particularly those with PD-L1-positive disease, findings from the phase III IMmotion151* trial show.

Audrey Abella, 27 Feb 2018
The combination regimen comprising gemcitabine and nab*-paclitaxel (GNP) exhibited similar potential with FOLFIRINOX** in downstaging and improving survival rates in pancreatic cancer, according to several studies presented at the ASCO Gastrointestinal Cancers Symposium 2018 (ASCO GI 2018).
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download